HMGB1-Driven Inflammation and Intimal Hyperplasia After Arterial Injury Involves Cell-Specific Actions Mediated by TLR4

Objective—Endoluminal vascular interventions such as angioplasty initiate a sterile inflammatory response resulting from local tissue damage. This response drives the development of intimal hyperplasia (IH) that, in turn, can lead to arterial occlusion. We hypothesized that the ubiquitous nuclear protein and damage-associated molecular pattern molecule, high-mobility group box 1 (HMGB1), is one of the endogenous mediators that activates processes leading to IH after endoluminal injury to the arterial wall. The aim of this study is to investigate whether approaches that reduce the levels of HMGB1 or inhibit its activity suppresses IH after arterial injury. Approach and Results—Here, we show that HMGB1 regulates IH in a mouse carotid wire injury model. Induced genetic deletion or neutralization of HMGB1 prevents IH, monocyte recruitment, and smooth muscle cell growth factor production after endoluminal carotid artery injury. A specific inhibitor of HMGB1 myeloid differentiation factor 2–toll-like receptor 4 (TLR4) interaction, P5779, also significantly inhibits IH. HMGB1 deletion is mimicked in this model by global deletion of TLR4 and partially replicated by myeloid-specific deletion of TLR4 but not TLR2 or receptor for advanced glycation endproducts deletion. The specific HMGB1 isoform known to activate TLR4 signaling (disulfide HMGB1) stimulates smooth muscle cell to migrate and produce monocyte chemotactic protein 1/CCL2) via TLR4. Macrophages produce smooth muscle cell mitogens in response to disulfide HMGB1 also in a TLR4/myeloid differentiation primary response gene (88)/Trif-dependent manner. Conclusions—These findings place HMGB1 and its receptor, TLR4 as critical regulators of the events that drive the inflammation leading to IH after endoluminal arterial injury and identify this pathway as a possible therapeutic target to limit IH to attenuate damage-associated molecular pattern molecule–mediated vascular inflammatory responses.

[1]  Jingjing Cai,et al.  The Role of HMGB1 in Cardiovascular Biology: Danger Signals. , 2015, Antioxidants & redox signaling.

[2]  K. Tracey,et al.  MD-2 is required for disulfide HMGB1–dependent TLR4 signaling , 2015, The Journal of experimental medicine.

[3]  K. Tracey,et al.  A Systematic Nomenclature for the Redox States of High Mobility Group Box (HMGB) Proteins , 2014, Molecular medicine.

[4]  M. Bianchi,et al.  HMGB1 and leukocyte migration during trauma and sterile inflammation. , 2013, Molecular immunology.

[5]  D. Stolz,et al.  Cellular‐specific role of toll‐like receptor 4 in hepatic ischemia‐reperfusion injury in mice , 2013, Hepatology.

[6]  K. Tracey,et al.  The many faces of HMGB1: molecular structure‐functional activity in inflammation, apoptosis, and chemotaxis , 2013, Journal of leukocyte biology.

[7]  K. Kent,et al.  Local drug delivery to prevent restenosis. , 2013, Journal of vascular surgery.

[8]  M. Lotze,et al.  Signaling of High Mobility Group Box 1 (HMGB1) through Toll-like Receptor 4 in Macrophages Requires CD14 , 2013, Molecular Medicine.

[9]  M. Lotze,et al.  A Janus Tale of Two Active High Mobility Group Box 1 (HMGB1) Redox States , 2012, Molecular medicine.

[10]  K. Tracey,et al.  Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release , 2012, The Journal of experimental medicine.

[11]  J. Hamming,et al.  Blocking Toll-Like Receptors 7 and 9 Reduces Postinterventional Remodeling via Reduced Macrophage Activation, Foam Cell Formation, and Migration , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[12]  K. Tracey,et al.  Redox Modification of Cysteine Residues Regulates the Cytokine Activity of High Mobility Group Box-1 (HMGB1) , 2012, Molecular medicine.

[13]  M. Bots,et al.  Stenting Versus Surgery in Patients With Carotid Stenosis After Previous Cervical Radiation Therapy: Systematic Review and Meta-Analysis , 2012, Stroke.

[14]  H. Björkbacka,et al.  The vascular repair process after injury of the carotid artery is regulated by IL-1RI and MyD88 signalling. , 2011, Cardiovascular Research.

[15]  F. Eberli,et al.  Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial , 2011, Circulation.

[16]  J. Jukema,et al.  Toll-Like Receptor 4 Is Involved in Human and Mouse Vein Graft Remodeling, and Local Gene Silencing Reduces Vein Graft Disease in Hypercholesterolemic APOE*3Leiden Mice , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[17]  M. Lotze,et al.  High-mobility group box 1, oxidative stress, and disease. , 2011, Antioxidants & redox signaling.

[18]  K. Tracey,et al.  HMGB1 is a therapeutic target for sterile inflammation and infection. , 2011, Annual review of immunology.

[19]  M. Tao,et al.  Rationale and practical techniques for mouse models of early vein graft adaptations. , 2010, Journal of vascular surgery.

[20]  T. Billiar,et al.  Dominant role of the MyD88-dependent signaling pathway in mediating early endotoxin-induced murine ileus. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[21]  A. Davies,et al.  Toll-Like Receptor-2 Mediates Inflammation and Matrix Degradation in Human Atherosclerosis , 2009, Circulation.

[22]  S. Akira,et al.  HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses , 2009, Nature.

[23]  S. Eddahibi,et al.  Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice , 2009, Respiratory research.

[24]  Sun-Dong Park,et al.  Rhein Inhibits TNF-α-Induced Human Aortic Smooth Muscle Cell Proliferation via Mitochondrial-Dependent Apoptosis , 2009, Journal of Vascular Research.

[25]  Andreas Schober,et al.  Chemokines in Atherosclerosis , Thrombosis , and Vascular Biology Series , 2008 .

[26]  D. Greaves,et al.  CCR2-Mediated Antiinflammatory Effects of Endothelial Tetrahydrobiopterin Inhibit Vascular Injury–Induced Accelerated Atherosclerosis , 2008, Circulation.

[27]  C. Dintsios,et al.  Intravascular brachytherapy for peripheral vascular disease , 2008, GMS Health Technology Assessment.

[28]  D. Hui.  Intimal hyperplasia in murine models. , 2008, Current drug targets.

[29]  M. Nobuyoshi,et al.  HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. , 2007, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[30]  A. Maseri,et al.  Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  P. Quax,et al.  Anti–MCP-1 Gene Therapy Inhibits Vascular Smooth Muscle Cells Proliferation and Attenuates Vein Graft Thickening Both In Vitro and In Vivo , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[32]  K. Tracey,et al.  Role of HMGB1 in apoptosis-mediated sepsis lethality , 2006, The Journal of Experimental Medicine.

[33]  K. Tracey,et al.  Cutting Edge: High-Mobility Group Box 1 Preconditioning Protects against Liver Ischemia-Reperfusion Injury1 , 2006, The Journal of Immunology.

[34]  N. Kalinina,et al.  Increased Expression of the DNA-Binding Cytokine HMGB1 in Human Atherosclerotic Lesions: Role of Activated Macrophages and Cytokines , 2004 .

[35]  E. Pålsson-McDermott,et al.  Signal transduction by the lipopolysaccharide receptor, Toll‐like receptor‐4 , 2004, Immunology.

[36]  N. Kalinina,et al.  Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[37]  P. Quax,et al.  Toll-Like Receptor 4 Is Involved in Outward Arterial Remodeling , 2004, Circulation.

[38]  K. Tracey,et al.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  B. Rollins,et al.  MCP-1 deficiency is associated with reduced intimal hyperplasia after arterial injury. , 2003, Biochemical and biophysical research communications.

[40]  A. Zwinderman,et al.  Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events , 2003, Circulation.

[41]  Michael Bustin,et al.  Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. , 2003, Blood.

[42]  F. Welt,et al.  Inflammation and Restenosis in the Stent Era , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[43]  J. Sluijter,et al.  In Vivo Evidence for a Role of Toll-Like Receptor 4 in the Development of Intimal Lesions , 2002, Circulation.

[44]  G. Dangas,et al.  Cardiology patient page. Restenosis: repeat narrowing of a coronary artery: prevention and treatment. , 2002, Circulation.

[45]  S. Akira,et al.  Toll-like receptors: critical proteins linking innate and acquired immunity , 2001, Nature Immunology.

[46]  S. Müller,et al.  The High Mobility Group (Hmg) Boxes of the Nuclear Protein Hmg1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells , 2001, The Journal of cell biology.

[47]  A. Aguzzi,et al.  The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice , 1999, Nature Genetics.

[48]  Amit Kumar,et al.  Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[49]  P. Bossuyt,et al.  Angiographic risk factors of luminal narrowing after coronary balloon angioplasty using balloon measurements to reflect stretch and elastic recoil at the dilation site. The CARPORT Study Group. , 1992, The American journal of cardiology.

[50]  Spencer B. King,et al.  Restenosis After Coronary Angioplasty: Potential Biologic Determinants and Role of Intimal Hyperplasia , 1989 .

[51]  Yue Zheng,et al.  Damage-Associated Molecular Patterns , and Sterile Inflammation in Cardiovascular Disease , 2011 .

[52]  J. Jukema,et al.  Toll-Like Receptor 4 Is Involved in Human and Mouse Vein Graft Remodeling , and Local Gene Silencing Reduces Vein Graft Disease in Hypercholesterolemic APOE * 3 Leiden Mice , 2011 .

[53]  G. Dangas,et al.  Cardiology patient page. Restenosis: repeat narrowing of a coronary artery: prevention and treatment. , 2002, Circulation.

[54]  S. Müller,et al.  The High Mobility Group ( HMG ) Boxes of the Nuclear Protein HMG 1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells , 2001 .